974-P: Associations between Patient Characteristics and Cardiovascular Disease: A Post-hoc Analysis from the CAPTURE Study

Objective: The CAPTURE study found that the prevalence of CVD in adults with T2D is approximately 1 in 3. This post hoc analysis determined the association between CVD risk factors (RF) and CVD. Methods: CAPTURE was a cross-sectional, non-interventional study in people with T2D across 13 countries. Participant data were collected during a single routine clinical visit in a primary or specialist settings between Dec 1, 2018 and Sep, 2019. A multivariable logistic regression model was used to calculate prevalence odds ratios (PORs). Results: Data were from 6369 participants with the information available for all included variables from the total CAPTURE population (N=9823). Age and CKD (assessed by eGFR) were positively associated with CVD status (both p Conclusion: The high CVD prevalence in the CAPTURE study is associated with demographics, classic CVD RF and diabetes-related variables, especially CKD. A negative association with LDL-C reflect confounding through indication for the use of lipid-lowering agents. These data support the use of antidiabetes drugs with proven CV benefit on several CV RFs in people with T2D and CVD. Disclosure A. M. Alguwaihes: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi. C. Lengyel: Other Relationship; Self; AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, EGIS, KRKA, Lilly Hungaria Kft, MSD Corporation, Novartis AG, Novo Nordisk, Pfizer Inc., Richter Gedeon, Sandoz International GmbH, Sanofi-Aventis, Servier Laboratories, Teva Pharmaceutical Industries Ltd., Worwag Pharma. O. Mosenzon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., BOL Pharma, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. G. T. Russo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. S. Shirabe: Other Relationship; Self; Merck Sharp & Dohme Corp., Novo Nordisk, Sumitomo Dainippon Pharma Co., Ltd. K. Urbancova: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., MSD Corporation, Novo Nordisk, Zentiva. S. Vencio: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk, Other Relationship; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk, Speaker’s Bureau; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. G. Yadav: Employee; Self; Novo Nordisk. J. A. Leon: Advisory Panel; Self; AstraZeneca, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Research Support; Self; Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi, Takeda Pharmaceutical Co., Speaker’s Bureau; Self; AstraZeneca, Merck & Co., Inc., Merck Sharp & Dohme Corp., Novo Nordisk. F. Bayram: Advisory Panel; Self; Novo Nordisk A/S, Sanofi Genzyme, Consultant; Self; Lilly Diabetes, Novo Nordisk, Pfizer Inc. P. Darmon: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Mundipharma International, Novartis AG, Novo Nordisk, Sanofi, Research Support; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Mundipharma International, Novartis AG, Novo Nordisk, Sanofi. T. Davis: Advisory Panel; Self; Merck Sharp & Dohme Corp. Speaker9s Bureau; Self; Novo Nordisk. Other Relationship; Self; Novo Nordisk. G. Dieuzeide: Advisory Panel; Self; AstraZeneca, Novo Nordisk, Roche Diagnostic USA, Sanofi. Speaker9s Bureau; Self; AstraZeneca, Novo Nordisk, Roche Diagnostic USA, Sanofi. K.T. Eriksen: Employee; Self; Novo Nordisk. T. Hong: Speaker9s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi. T.J. Jensen: Employee; Self; Novo Nordisk. C. Lengyel: Other Relationship; Self; AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim International GmbH, EGIS, KRKA, Lilly Hungaria Kft, MSD Corporation, Novartis AG, Novo Nordisk, Pfizer Inc., Richter Gedeon, Sandoz International GmbH, Sanofi-Aventis, Servier Laboratories, Teva Pharmaceutical Industries Ltd., Worwag Pharma. O. Mosenzon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., BOL Pharma, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. Research Support; Self; AstraZeneca, Novo Nordisk. Speaker9s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. G.T. Russo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. Speaker9s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk, Sanofi. S. Shirabe: Other Relationship; Self; Merck Sharp & Dohme Corp., Novo Nordisk, Sumitomo Dainippon Pharma Co., Ltd. K. Urbancova: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MSD Corporation, Novo Nordisk. Speaker9s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., MSD Corporation, Novo Nordisk, Zentiva. S. Vencio: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. Speaker9s Bureau; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. Other Relationship; Self; Boehringer Ingelheim International GmbH, Novartis AG, Novo Nordisk. G. Yadav: Employee; Self; Novo Nordisk.